Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Neoplasms of the CNS

  Free Subscription


1 Brain
4 Clin Cancer Res
1 Int J Radiat Oncol Biol Phys
7 J Neurooncol
8 J Neurosurg
5 Neuro Oncol
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. HERBET G, Duffau H, Mandonnet E
    Predictors of cognition after glioma surgery: connectotomy, structure-function phenotype, plasticity.
    Brain. 2024 Apr 4:awae093. doi: 10.1093.
    PubMed         Abstract available

    Clin Cancer Res

  2. HANSFORD JR, Das A, McGee RB, Nakano Y, et al
    Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors.
    Clin Cancer Res. 2024 Apr 4. doi: 10.1158/1078-0432.CCR-23-4033.
    PubMed         Abstract available

  3. CICCONE R, Quintarelli C, Camera A, Pezzella M, et al
    GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma.
    Clin Cancer Res. 2024 Mar 29. doi: 10.1158/1078-0432.CCR-23-1880.
    PubMed         Abstract available

  4. LYNCE F, Lin NU
    From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors.
    Clin Cancer Res. 2024;30:1217-1219.
    PubMed         Abstract available

  5. STANISZEWSKA AD, Pilger D, Gill SJ, Jamal K, et al
    Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
    Clin Cancer Res. 2024;30:1338-1351.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  6. ONG WL, Stewart J, Sahgal A, Soliman H, et al
    Predictors of tumour dynamics over a 6-week course of concurrent chemoradiotherapy for glioblastoma and the impact on survival.
    Int J Radiat Oncol Biol Phys. 2024 Mar 30:S0360-3016(24)00453.
    PubMed         Abstract available

    J Neurooncol

  7. TONG E, Horsley P, Wheeler H, Wong M, et al
    Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    J Neurooncol. 2024 Mar 29. doi: 10.1007/s11060-024-04643.
    PubMed         Abstract available

  8. JOST J, Volker K, Brandt R, Stummer W, et al
    Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status.
    J Neurooncol. 2024 Apr 1. doi: 10.1007/s11060-024-04629.
    PubMed         Abstract available

  9. XIANG Y, Chen Y, Xu Z, Zhou S, et al
    Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04662.
    PubMed         Abstract available

  10. LU VM, Brun JD, Niazi TN, Brun JD, et al
    Pediatric neurosurgical medulloblastoma outcomes in La Paz, Bolivia: How a Lower Middle-Income Country (LMIC) institution in South America compares to the United States.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04664.
    PubMed         Abstract available

  11. DMUKAUSKAS M, Cioffi G, Waite KA, Sloan AE, et al
    Sex differences in adverse events in Medicare individuals >/= 66 years of age post glioblastoma treatment.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04652.
    PubMed         Abstract available

  12. MAHMOODIFAR S, Pangal DJ, Neman J, Zada G, et al
    Comparative analysis of the spatial distribution of brain metastases across several primary cancers using machine learning and deep learning models.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04630.
    PubMed         Abstract available

  13. MIRZAYEVA L, Ucar M, Kaymaz AM, Temel E, et al
    Intraoperative magnetic resonance imaging in glioma surgery: a single-center experience.
    J Neurooncol. 2024 Apr 3. doi: 10.1007/s11060-024-04660.
    PubMed         Abstract available

    J Neurosurg

  14. ZHANG S, Yao S, Chen J, Akter F, et al
    Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
    J Neurosurg. 2023;140:1019-1028.
    PubMed         Abstract available

  15. LUCIDO T, Rajkumar S, Rogowski B, Meinert J, et al
    The 5-factor modified frailty index as a prognostic factor of stereotactic radiosurgery for metastatic disease to the brain.
    J Neurosurg. 2023;140:929-937.
    PubMed         Abstract available

  16. VAZQUEZ S, Gold J, Spirollari E, Akmal S, et al
    The story of dexamethasone and how it became one of the most widely used drugs in neurosurgery.
    J Neurosurg. 2023 Nov 24:1-7. doi: 10.3171/2023.9.JNS231099.
    PubMed         Abstract available

  17. REN L, Xie Q, Deng J, Chen J, et al
    Association of frequent NF2 mutations with spinal location predominance and worse outcomes in psammomatous meningiomas.
    J Neurosurg. 2024 Mar 29:1-9. doi: 10.3171/2024.1.JNS232450.
    PubMed         Abstract available

  18. KONECNA D, Vymola P, Ternerova N, Vymolova B, et al
    Molecularly targeted protease-activated probes for visualization of glioblastoma: a comparison with 5-ALA.
    J Neurosurg. 2024 Mar 29:1-12. doi: 10.3171/2024.1.JNS231137.
    PubMed         Abstract available

    Erratum. Grade 3 meningioma survival and recurrence outcomes in an international multicenter cohort.
    J Neurosurg. 2024 Mar 29:1. doi: 10.3171/2024.2.JNS23465.

  20. MERENZON MA, Mendez Valdez MJ, Chandar J, Lu VM, et al
    Minimally invasive keyhole approach for supramaximal frontal glioma resections: technical note.
    J Neurosurg. 2023;140:949-957.
    PubMed         Abstract available

  21. ASFAW ZK, Hernandez-Marquez GC, Naik A, Young T, et al
    The intersection of race and social determinants of health on clinical outcome of glioblastoma patients.
    J Neurosurg. 2024 Apr 5:1-10. doi: 10.3171/2024.1.JNS232702.
    PubMed         Abstract available

    Neuro Oncol

  22. OBRECHT-STURM D, Schomig L, Mynarek M, Bison B, et al
    Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment.
    Neuro Oncol. 2024 Apr 5:noae071. doi: 10.1093.
    PubMed         Abstract available

  23. RICKLEFS FL, Wollmann K, Salviano-Silva A, Drexler R, et al
    Circulating extracellular vesicles as biomarker for diagnosis, prognosis and monitoring in glioblastoma patients.
    Neuro Oncol. 2024 Apr 3:noae068. doi: 10.1093.
    PubMed         Abstract available

  24. XIE H, Jiang Y, Xiang Y, Wu B, et al
    Super-enhancer-driven LIF promotes the mesenchymal transition in glioblastoma by activating ITGB2 signaling feedback in microglia.
    Neuro Oncol. 2024 Mar 30:noae065. doi: 10.1093.
    PubMed         Abstract available

  25. DE LA NAVA D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, et al
    The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
    Neuro Oncol. 2024 Mar 30:noae066. doi: 10.1093.
    PubMed         Abstract available

  26. IVANIDZE J, Chang SJ, Haghdel A, Kim JT, et al
    [Ga68] DOTATATE PET/MRI-Guided Radiosurgical Treatment Planning and Response Assessment in Meningiomas.
    Neuro Oncol. 2024 Mar 30:noae067. doi: 10.1093.
    PubMed         Abstract available

    PLoS One

  27. SUN B, Lu W, Yu W, Tian Y, et al
    Prevalence and risk factors of early postoperative seizures in patients with glioma: A protocol for meta-analysis and systematic review.
    PLoS One. 2024;19:e0301443.
    PubMed         Abstract available

  28. WANG L, Wang H, D'Angelo F, Curtin L, et al
    Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm.
    PLoS One. 2024;19:e0299267.
    PubMed         Abstract available

  29. JAMBOR I, Steiner A, Pesola M, Gardberg M, et al
    Relaxation Along a Fictitious Field, continuous wave T1rho, adiabatic T1rho and adiabatic T2rho imaging of human gliomas at 3T: A feasibility study.
    PLoS One. 2024;19:e0296958.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.